Asset Details
Do you wish to reserve the book?
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
Do you wish to request the book?
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
2018
Overview
Photothermal therapy (PTT) has received extensive attention owing to its non-invasive nature and highly therapeutic outcomes. PTT agents and near-infrared (NIR) laser are essential elements in PTT. However, most PTT agents are composed of heavy metals, characterized by serious cytotoxicity and side effects, and NIR irradiation often damages normal tissue owing to the high dose, thus limiting the clinical application of PTT.
In this regard, exploring new perspectives enabling more PTT agents to be enriched into the tumor and NIR laser irradiation decay in PTT is vital.
In this study, cetuximab (Ab), an anti-angiogenic antibody which targets the EGFR, was modified on CuS NPs (CuS-Ab NPs) to improve the aggregation of CuS NPs in the tumor.
The cellular uptake data and the biodistribution results showed comparable accumulation of CuS-Ab NPs in tumor, thus decreasing the cytotoxicity and side effects in normal tissues. More importantly, the modification of Ab in CuS-Ab NPs impressively inhibited the formation and progression of tumor vessels, as demonstrated by immunohistochemistry staining. The introduction of anti-vessel treatment requires CuS-Ab NPs to provide weak PTT, which means that a small amount of laser energy is required, inevitably causing negligible damage to normal tissue.
Therefore, our tailor-made CuS-Ab NPs have promising potential in clinical applications.
Publisher
Informa UK Limited,Dove Medical Press Limited,Taylor & Francis Ltd,Dove Press,Dove Medical Press
Subject
/ Animals
/ Chickens
/ Copper
/ CuS NPs
/ EGFR
/ Ethylenediaminetetraacetic acid
/ Female
/ Graphene
/ Human Umbilical Vein Endothelial Cells
/ Human Umbilical Vein Endothelial Cells - metabolism
/ Humans
/ International Journal of Nanomedicine
/ Lasers
/ Nanoparticles - ultrastructure
/ Neovascularization, Pathologic
/ Neovascularization, Pathologic - diagnostic imaging
/ Neovascularization, Pathologic - drug therapy
/ Neovascularization, Pathologic - pathology
/ Neovascularization, Pathologic - therapy
/ Peptides
/ R5-920
